Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer
NCT04452370
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Triple Negative Breast Cancer
Interventions
DRUG:
oral etoposide + anlotinib
Sponsor
Chinese Academy of Medical Sciences